-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Risk Re-Stratification Based on Black AML Patient Exome Data

Program: Special-Interest Sessions
Session: Race and Ancestry in Precision Medicine
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Genomics, Diversity, Equity, and Inclusion (DEI), Diseases, Myeloid Malignancies, Biological Processes
Sunday, December 8, 2024, 4:30 PM-5:45 PM

Ann-Kathrin Eisfeld, MD

The Ohio State University, Columbus, OH

Disclosures: Eisfeld: OncLive: Honoraria; Karyopharm Therapeutics: Other: Spouse employment; GTC: Honoraria; Dava Oncology: Honoraria; AstraZeneca US: Membership on an entity's Board of Directors or advisory committees; VJ HemeOnc: Honoraria.

See more of: Race and Ancestry in Precision Medicine
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>